Skip to content


Medical and radiation oncology

Section edited by Dirk Vordermark

This section focuses on clinical research that impacts on the treatment of cancer using systemic chemotherapy, targeted therapy, and radiation.

Page 3 of 26
  1. Content type: Research article

    Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker recommended in clinical guidelines as a first-li...

    Authors: Ping-Tee Tan, Mohamed Ismail Abdul Aziz, Fiona Pearce, Wan-Teck Lim, David Bin-Chia Wu and Kwong Ng

    Citation: BMC Cancer 2018 18:352

    Published on:

  2. Content type: Case report

    We report the successful treatment of the patient with osimertinib 80 mg/day following disease progression and a discordance in the detection of a mechanism of resistance epithelial growth factor receptor (EGF...

    Authors: Isa Mambetsariev, Lalit Vora, Kim Wai Yu and Ravi Salgia

    Citation: BMC Cancer 2018 18:314

    Published on:

  3. Content type: Research article

    Prediction of the outcome of sorafenib therapy using biomarkers is an unmet clinical need in patients with advanced hepatocellular carcinoma (HCC). The aim was to develop and validate a biomarker-based model f...

    Authors: Hwi Young Kim, Dong Hyeon Lee, Jeong-Hoon Lee, Young Youn Cho, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim and Jung-Hwan Yoon

    Citation: BMC Cancer 2018 18:307

    Published on:

  4. Content type: Research article

    The expression of circular RNA (circRNA) may affect tumor progression. However, there have been no systemic meta-analysis for cancer diagnosis by using circRNAs in clinical till now. Herein, we aimed to collec...

    Authors: Miao Wang, Yuxi Yang, Jian Xu, Wen Bai, Xueli Ren and Huijian Wu

    Citation: BMC Cancer 2018 18:303

    Published on:

  5. Content type: Case report

    Everolimus was recently approved for the treatment of neuroendocrine tumors. However, its efficacy and tolerability in hemodialysis patients with end-stage renal disease is not established.

    Authors: M. P. Brizzi, A. La Salvia, M. Tampellini, C. Sonetto, M. Volante and G. V. Scagliotti

    Citation: BMC Cancer 2018 18:311

    Published on:

  6. Content type: Research article

    In patients with metastatic renal cell cancer, based on limited evidence, increased sunitinib exposure is associated with better outcome. The survival and toxicity data of patients receiving individualized dos...

    Authors: Anikó Maráz, Adrienn Cserháti, Gabriella Uhercsák, Éva Szilágyi, Zoltán Varga, János Révész, Renáta Kószó, Linda Varga and Zsuzsanna Kahán

    Citation: BMC Cancer 2018 18:296

    Published on:

  7. Content type: Research article

    Trastuzumab (Herceptin® [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer. However, there is a paucity of data availabl...

    Authors: Volkmar Müller, Michael Clemens, Jacek Jassem, Nedal Al-Sakaff, Petra Auclair, Eveline Nüesch, Debbie Holloway, Mona Shing and Yung-Jue Bang

    Citation: BMC Cancer 2018 18:295

    Published on:

  8. Content type: Research article

    To compare the prevalence of nephrotoxicity between patients with a solitary-functioning kidney versus those with bilateral-functioning kidneys during the administration of cisplatin-based chemotherapy for adv...

    Authors: Takamitsu Inoue, Jun Miyazaki, Daishi Ichioka, Shintaro Narita, Susumu Kageyama, Mikio Sugimoto, Koji Mitsuzuka, Yusuke Shiraishi, Hidefumi Kinoshita, Hironobu Wakeda, Takeshi Nomoto, Eiji Kikuchi, Yoshiyuki Matsui, Keiko Fujie, Tomonori Habuchi and Hiroyuki Nishiyama

    Citation: BMC Cancer 2018 18:290

    Published on:

  9. Content type: Research article

    Mainly because of the diversity of clinical presentations, diagnostic delays in lymphoma can be excessive. The time spent in primary care before referral to the specialist may be relatively short compared with...

    Authors: Xavier Bosch, Carmen Sanclemente-Ansó, Ona Escoda, Esther Monclús, Jonathan Franco-Vanegas, Pedro Moreno, Mar Guerra-García, Neus Guasch and Alfons López-Soto

    Citation: BMC Cancer 2018 18:276

    Published on:

  10. Content type: Research article

    The primary pulmonary lymphoma (PPL), with a low incidence, was highly misdiagnosed in clinic. The present study analyzes the clinical features, laboratory and imaging data, pathologic characteristics, and sum...

    Authors: D. Yao, L. Zhang, P. L. Wu, X. L. Gu, Y. F. Chen, L. X. Wang and X. Y. Huang

    Citation: BMC Cancer 2018 18:281

    Published on:

  11. Content type: Research article

    Here we assessed the influence of androgen deprivation therapy (ADT) during and/or after post-prostatectomy radiotherapy (RT) on biochemical recurrence (BCR) and radiographic progression in patients with prost...

    Authors: Myong Kim, Cheryn Song, In Gab Jeong, Seung-Kwon Choi, Myungchan Park, Myungsun Shim, Young Seok Kim, Dalsan You, Jun Hyuk Hong, Choung-Soo Kim and Hanjong Ahn

    Citation: BMC Cancer 2018 18:271

    Published on:

  12. Content type: Research article

    Several systemic treatments have been shown to increase survival for patients with metastatic castration-resistant prostate cancer. This study sought to characterize variation in use of the six “focus drugs” (...

    Authors: Megan E. V. Caram, Jason P. Estes, Jennifer J. Griggs, Paul Lin and Bhramar Mukherjee

    Citation: BMC Cancer 2018 18:258

    Published on:

  13. Content type: Research article

    Oxaliplatin is a platinum derivative that has shown efficacy in advanced hepatocellular carcinoma. S-1 is an oral fluoropyrimidine that has substituted for 5-fluorouracil in many cancers. This was a multicente...

    Authors: Dae-Won Lee, Kyung-Hun Lee, Hee-Jun Kim, Tae-Yong Kim, Jin-Soo Kim, Sae-Won Han, Do-Youn Oh, Jee Hyun Kim, Seock-Ah Im and Tae-You Kim

    Citation: BMC Cancer 2018 18:252

    Published on:

  14. Content type: Research article

    Esophageal sarcomatoid carcinoma (ESC) is a rare disease with a mixture of both carcinomatous and sarcomatous components in the tumor. Its genetic background and mechanisms of oncogenesis remain largely unknown.

    Authors: Hongyang Lu, Shifeng Yang, Huineng Zhu, Xiaoling Tong, Fajun Xie, Jing Qin, Na Han, Xue Wu, Yun Fan, Yang W. Shao and Weimin Mao

    Citation: BMC Cancer 2018 18:251

    Published on:

  15. Content type: Research article

    There is no consensus regarding the optimal time to initiate adjuvant chemotherapy after surgery for stage III colon cancer, and the relevant postoperative complications that cause delays in adjuvant chemother...

    Authors: Peng Gao, Xuan-zhang Huang, Yong-xi Song, Jing-xu Sun, Xiao-wan Chen, Yu Sun, Yu-meng Jiang and Zhen-ning Wang

    Citation: BMC Cancer 2018 18:234

    Published on:

  16. Content type: Case report

    Immune checkpoint inhibitors (ICPIs) are being investigated in clinical trials for patients with glioblastoma. While these therapies hold great promise, management of the patients receiving such treatment can ...

    Authors: Surabhi Ranjan, Martha Quezado, Nancy Garren, Lisa Boris, Christine Siegel, Osorio Lopes Abath Neto, Brett J. Theeler, Deric M. Park, Edjah Nduom, Kareem A. Zaghloul, Mark R. Gilbert and Jing Wu

    Citation: BMC Cancer 2018 18:239

    Published on:

  17. Content type: Research article

    The immune system has a known role in the aetiology, progression and final treatment outcome of oral squamous cell cancers. The aim of this study was to evaluate the influence of radical surgery and radiothera...

    Authors: Tadej Dovšak, Alojz Ihan, Vojko Didanovič, Andrej Kansky, Miha Verdenik and Nataša Ihan Hren

    Citation: BMC Cancer 2018 18:235

    Published on:

Page 3 of 26